According to Sanofi-Aventis, Apidra is indicated to improve glycemic control in adults and children (four years and older) with type 1 diabetes or adults with type 2 diabetes.
The availability of Apidra SoloSTAR, approved in the US in February 2009, follows the approval and launch of Lantus SoloSTAR in 2007.
Apidra SoloSTAR and Lantus SoloSTAR are designed with different colors and tactile differentiation to help patients differentiate between the two pens, which are intended for use with two very different types of insulins, the company said.
Jerry Durso, vice president of specialized therapeutics business unit at Sanofi-Aventis US, said: “Sanofi-Aventis is committed to providing innovative tools to patients with diabetes that can help ease some of the challenges of blood sugar management. Apidra SoloSTAR provides patients with a convenient option for administering their Apidra.”